Abstract:
A method of extracting key frames from a video sequence, which video sequence comprises MPEG compressed video data having block motion vectors. The method initially partially decompresses (202) the MPEG compressed video data to obtain block motion vectors and converts (204) the block motion vectors to forward block motion vectors. The method then generates (206) global motion signals and generates (306) dominant global direction clusters. The method then selects (402, 404, 406) potential key frames of the video sequence using the generated dominant global direction clusters. The method lastly decompresses (408) the selected key frames to obtain the extracted key frames.
Abstract:
A built-in, self-test (BIST) network employs a hierarchy of Universal BIST schedulers (UBSs) for scheduling and coordinating testing of elements, such as regular structure BISTed (RSB) elements and random logic BISTed (RLB) elements. Individual UBSs are preferably positioned in local areas, or sections, of an integrated circuit for testing of RSB and RLB elements within the local area. Testing of RSB and RLB elements within the local area allows the BIST network to minimize effects of delay and clock skew by employing relatively short interconnect routing between BISTed elements. Each of the individual UBSs are, in turn, controlled by a master UBS (MUBS) via simplified timing of control signals. The MUBS also may interface with an external testing device that initiates BISTed testing.
Abstract:
Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.
Abstract:
Described are mechanisms and techniques for enabling incremental non-chronological synchronization of namespaces. In an environment, entities must have unique names within a namespace and entities may only refer to entities that actually exist within the namespace. Synchronizing two such namespaces involves providing a mechanism for indicating that an entity has been created because a reference to that entity has been made even though that entity does not yet exist. At such time as the entity is formally created, the indication is removed. Synchronizing two such namespaces also involves providing a mechanism for indicating that an entity's unique name in the namespace has been compromised through the synchronization process.
Abstract:
Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.
Abstract:
An Explicit Congestion Notification (ECN) method is disclosed for wireless applications to avoid network congestion in a TCP/IP packet-switched network. Such method comprises transmitting, at a source node, data packets to a destination node, via at least an intermediate node; determining, at the intermediate node, if an incipient congestion is encountered, setting a Congestion Experienced (CE) flag in each data packet to notify congestion; sending, at the destination node, an ECN-Echo acknowledgment packet back to the source node to inform congestion; reducing, at the source node, a congestion window and a transmission rate to avoid congestion; if the packet loss is due to congestion, re-transmitting, at the source node, only a lost packet to the destination node; alternatively, if the packet loss is due to transmission error, re-transmitting, the lost packet to the destination node, while increasing a round-trip timeout but maintaining the same congestion window.
Abstract:
Apparatus and method useful in the process of making a forming tool, such as metal stamping tool. The apparatus (20, 22) performs a method of scanning a working surface (18) of a tool part (14) with an optical shape measurement camera (22) to obtain electronic images from different views of the working surface, and then processing the electronic images to develop a first set of data defining the three-dimensional shape of the working surface. The first set of data is then processed with a second set of data having a correlation with the shape of the working surface to develop a third set of data defining differences between the first and second sets of data. The second set of data may define the shape of a part formed by the tool or the master shape of the part.
Abstract:
A method for reducing blurring associated with objects forming part of a grey scale image. The method includes receiving (11) a set of image pixels and then calculating (12) a gradient value for each one of the image pixels in the set. A selecting step (13) selects candidate object edge pixels from the image pixels by comparing the gradient value for each one of the image pixels in the set with a threshold value. A determining step (14) then determines a distribution of number candidate object edge pixels with specific grey level values. Thereafter, candidate object edge pixels within said distribution that have the same grey level values are identically non-linearly modified at a modifying step 15.
Abstract:
Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.
Abstract:
Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.